- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Improving the Care Continuum
An expert advises how to optimize the care continuum for patients with ASCVD.
EP: 1.The Burden of ASCVD and Evidence-Based Guidelines
EP: 2.A Patient’s Post-MI Journey
EP: 3.Improving the Care Continuum
EP: 4.Residual Cardiovascular Risk
EP: 5.Who is an Ideal Patient for Early Intensive Lipid Lowering?
EP: 6.Finding the Optimal Statin Dose
EP: 7.Therapy Beyond Statins in the Inpatient Setting
EP: 8.Using Adjunct Therapies in LDL Management
EP: 9.Ensuring Continuity of Care for the ASCVD Patient
EP: 10.Unmet Needs in Lipid Management
EP: 11.Defining “Optimal Care” for ASCVD Within Health Systems
EP: 12.What Does a Multidisciplinary Team Look Like?
EP: 13.The Future of LDL Management for Patients With High-Risk ASCVD
EP: 14.Enhancing Patient Care Through Guideline Adherence
EP: 15.Improving Access to PCSK9 Inhibitors in the Inpatient Setting
EP: 16.Appropriate ASCVD Treatment Outside of Closed Health Systems
EP: 17.Utilizing Quality Metrics in ASCVD
EP: 18.Improving Patient and Provider Engagement
EP: 19.Treatment Disparities in the Management of ASCVD
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
